Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NR4A3
REST API REST API
Homo sapiens
NR4A3 is differentially expressed in 319 experiments: 129 organism parts: lung, skeletal muscle, ... (127 more);, 190 disease states: normal, prostate carcinoma, ... (188 more);, 102 cell types 243 cell lines 47 compound treatments and 75 other conditions.
Synonyms NOR1, CSMF, MINOR, CHN
Orthologs E1BYS2_CHICK (Gallus gallus)   nr4a3 (Danio rerio)   Nr4a3 (Mus musculus)   NR4A3 (Bos taurus)   Nr4a3 (Rattus norvegicus)   Hr38 (Drosophila melanogaster)   nr4a2 (Xenopus laevis)   NR4A3 (Canis familiaris)   (Compare orthologs)
InterPro Term NOR1_rcpt, Nucl_hrmn_rcpt_lig-bd_core, Str_hrmn_rcpt, Znf_hrmn_rcpt, Nuc_orph_rcpt, Retinoic_acid_rcpt
Gene Ontology Term mesoderm formation, DNA binding, regulation of transcription, DNA-dependent, negative regulation of apoptosis, metal ion binding, biological_process, sequence-specific DNA binding, axon guidance, positive regulation of transcription from RNA polymerase II promoter, nucleus, receptor activity, transcription factor complex, positive regulation of cell cycle, adult behavior, binding, nucleoplasm, steroid hormone receptor activity, zinc ion binding, negative regulation of neuron apoptosis, steroid hormone mediated signaling pathway, gene expression, cellular response to stress, organ regeneration, neuromuscular process controlling balance, vestibular reflex, semicircular canal morphogenesis, response to peptide hormone stimulus, regulation of transcription from RNA polymerase II promoter by nuclear hormone receptor, hippocampus development, inner ear morphogenesis, thyroid hormone receptor activity, sequence-specific DNA binding transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, positive regulation of leukocyte apoptosis
UniProt Accession Q92570, Q6AW80, E9PBS2
Gene-Disease Assocation CHONDROSARCOMA, EXTRASKELETAL MYXOID, EWING SARCOMA; ES
Search EB-eye ENSG00000119508
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-3526, E-MTAB-62, E-GEOD-2280, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
HCC1143
2
E-MTAB-37, E-MTAB-62
PC3
2
E-GEOD-5258, E-MEXP-2034
primary culture
2
E-GEOD-2450, E-GEOD-1657
HEL9217
1
E-MTAB-37
hcaSMC
1
E-MTAB-62
237 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, E-GEOD-2822, ... (56 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
macrophage
1
3
E-GEOD-22373, E-GEOD-5099, E-GEOD-360, E-GEOD-8286
stromal cell
1
3
E-MEXP-2034, E-MEXP-1327, E-GEOD-3998, E-GEOD-10797
2
2
E-TABM-145, E-TABM-130
CD8+ T cell
2
E-GEOD-19069, E-AFMX-5
naive B cell
1
E-TABM-702
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (76 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
4
E-MTAB-62, E-MTAB-37, E-GEOD-7307, E-GEOD-96, E-MEXP-2034 ... (5 experiments)
gastric carcinoma
3
E-GEOD-2685, E-GEOD-15460, E-MTAB-37
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-MTAB-57
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-GEOD-2514
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
184 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-3720, E-TABM-868, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
none
5
7
E-GEOD-2706, E-MEXP-1958, E-GEOD-412, E-GEOD-22309, E-TABM-868, ... (12 experiments)
lipopolysaccharide
1
3
E-GEOD-3720, E-MEXP-1958, E-TABM-868, E-GEOD-2706
ethanol
2
E-MEXP-2241, E-MEXP-1014
glutathione
1
E-GEOD-2649
non-targeting
1
E-MEXP-2218
valproic acid
1
E-GEOD-1615
41 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
43 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-4619, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-GEOD-2466, E-GEOD-1926, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-6434, E-GEOD-1657, ... (9 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246, ... (7 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-21164, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922, E-TABM-147

Processing time: 0.327 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM